C49.20: Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip

C49.20, malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip, is listed as a covered diagnosis in 5 Medicare billing and coding articles that apply to 35 HCPCS Level II codes, including Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg), Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg), Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C49.20 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgCarrier judgment—1
Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgCarrier judgment—1
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mgCarrier judgment—1
Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mgSpecial coverage instructions apply—1
J9035Injection, bevacizumab, 10 mgCarrier judgment—1
J3590Unclassified biologicsCarrier judgment—1
C9257Injection, bevacizumab, 0.25 mgSpecial coverage instructions apply—1
Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mgCarrier judgment—1
J9267Injection, paclitaxel, 1 mgSpecial coverage instructions apply—1
J9264Injection, paclitaxel protein-bound particles, 1 mgCarrier judgment—1
J8999Prescription drug, oral, chemotherapeutic, nosSpecial coverage instructions apply—1
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—1
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—1
J8530Cyclophosphamide; oral, 25 mgSpecial coverage instructions apply—1
J8597Antiemetic drug, oral, not otherwise specifiedSpecial coverage instructions apply—1
J8610Methotrexate; oral, 2.5 mgSpecial coverage instructions apply—1
J8498Antiemetic drug, rectal/suppository, not otherwise specifiedSpecial coverage instructions apply—1
Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgramSpecial coverage instructions apply—1
Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramCarrier judgment—1
Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgramSpecial coverage instructions apply—1
J1442Injection, filgrastim (g-csf), excludes biosimilars, 1 microgramSpecial coverage instructions apply—1
J1449Injection, eflapegrastim-xnst, 0.1 mgCarrier judgment—1
J1447Injection, tbo-filgrastim, 1 microgramSpecial coverage instructions apply—1
Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mgCarrier judgment—1
Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mgCarrier judgment—1

10 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C49.20

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C49 diagnoses (Malignant neoplasm of other connective and soft tissue)

Frequently asked questions

Does Medicare cover C49.20 (Malignant neoplasm of connective and soft tissue of…)?

Medicare covers items and services, not diagnoses. 5 Medicare billing and coding articles list C49.20 as a covered diagnosis for 35 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C49.20?

The Level II codes from the policies most specific to this diagnosis are Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg, 1 article); Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg, 1 article); Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg, 1 article); Q5107 (Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg, 1 article); J9035 (Injection, bevacizumab, 10 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list C49.20?

A52370 (Billing and Coding: Bevacizumab and biosimilars); A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)); A52479 (Oral Anticancer Drugs - Policy Article), and 2 more articles.

What is ICD-10-CM code C49.20?

C49.20 is the ICD-10-CM code for malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip, in category C49 (Malignant neoplasm of other connective and soft tissue), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup